This find courtesy of Dr. Lakshmi Shankdhar via medical news today.
As a related aside, our SALSA group are preparing for active participation in a similar stem cell project which should begin over the coming three months. Stay tuned.
http://www.medicalnewstoday.com/releases/244306.php
Diabetic Amputations Reduced By Autologous Bone Marrow-Derived Mononuclear Cell Transplants (STEM CELL THERAPY)
Article Date: 20 Apr 2012 – 1:00 PDT
Cell Transplantation (20:10)
Autologous (self-donated) mononuclear cells derived from bone marrow (BMMNCs) have been found to significantly induce vascular growth when transplanted into patients with diabetes who are suffering from critical limb ischemia caused by peripheral artery disease (PAD), a complication of diabetes.
“Critical limb ischemia in diabetic patients is associated with high rates of morbidity and mortality; however, neovascularization induced by stem celltherapy could be a useful approach for these patients,” said study corresponding author Dr. Bernat Soria of the Andaluz Center for Biologic and Molecular Regenerative Medicine in Seville, Spain.
“In this study we evaluated the safety and efficacy of inter-arterial administration of autologous bone marrow-derived mononuclear cells with 20 diabetic patents with severe below-the-knee arterial ischemia.”
The researchers noted that surgical or endovascular revascularization options for patients such as those in the study are limited because of poor arterial outflow.
As previously reported, the one-year mortality rate for diabetic patients with PAD – most of which are associated with cardiac complications – has been found to be 20 %,” explained Dr. Soria.
“Our study documented significant increases in neovasculogenesis for the majority of our study patients and a decrease in the number of amputations. However, overall PAD mortality for our patients was similar to that generally experienced.”
The researchers concluded that BMMNC therapy for lower limb ischemia was a “safe procedure that generates a significant increase in the vascular network in ischemic areas” and promotes “remarkable clinical improvement.”
Diabetic Amputations Reduced By Autologous Bone Marrow-Derived Mononuclear Cell Transplants (STEM CELL THERAPY)
Article Date: 20 Apr 2012 – 1:00 PDT
Cell Transplantation (20:10)
Autologous (self-donated) mononuclear cells derived from bone marrow (BMMNCs) have been found to significantly induce vascular growth when transplanted into patients with diabetes who are suffering from critical limb ischemia caused by peripheral artery disease (PAD), a complication of diabetes.
“Critical limb ischemia in diabetic patients is associated with high rates of morbidity and mortality; however, neovascularization induced by stem celltherapy could be a useful approach for these patients,” said study corresponding author Dr. Bernat Soria of the Andaluz Center for Biologic and Molecular Regenerative Medicine in Seville, Spain.
“In this study we evaluated the safety and efficacy of inter-arterial administration of autologous bone marrow-derived mononuclear cells with 20 diabetic patents with severe below-the-knee arterial ischemia.”
The researchers noted that surgical or endovascular revascularization options for patients such as those in the study are limited because of poor arterial outflow.
As previously reported, the one-year mortality rate for diabetic patients with PAD – most of which are associated with cardiac complications – has been found to be 20 %,” explained Dr. Soria.
“Our study documented significant increases in neovasculogenesis for the majority of our study patients and a decrease in the number of amputations. However, overall PAD mortality for our patients was similar to that generally experienced.”
The researchers concluded that BMMNC therapy for lower limb ischemia was a “safe procedure that generates a significant increase in the vascular network in ischemic areas” and promotes “remarkable clinical improvement.”
This is quite interesting. They administered the cells transarterially. In our upcoming study, the stem cells will be injected intramuscularly.
http://www.ncbi.nlm.nih.gov/pubmed/22289660
To determine outcomes in such patients, we likely need new classification and outcome measures.